Tisotumab vedotin
Tivdak (tisotumab vedotin) is an antibody drug conjugate pharmaceutical. Tisotumab vedotin was first approved as Tivdak on 2021-09-20. The pharmaceutical is active against tissue factor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Clinical
Clinical Trials
13 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | 4 | — | — | — | 4 |
| Uterine cervical neoplasms | D002583 | — | — | 2 | 4 | — | — | — | 4 |
| Prostatic neoplasms | D011471 | — | C61 | 2 | 3 | — | — | — | 3 |
| Non-small-cell lung carcinoma | D002289 | — | — | 2 | 3 | — | — | — | 3 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 2 | 3 | — | — | — | 3 |
| Esophageal neoplasms | D004938 | — | C15 | 2 | 3 | — | — | — | 3 |
| Urinary bladder neoplasms | D001749 | — | C67 | 2 | 3 | — | — | — | 3 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | 2 | — | — | — | 2 |
| Neoplasms | D009369 | — | C80 | 1 | 1 | — | — | — | 1 |
| Fallopian tube neoplasms | D005185 | — | — | — | 1 | — | — | — | 1 |
Show 3 more
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tisotumab vedotin |
| INN | tisotumab vedotin |
| Description | Tisotumab vedotin, sold under the brand name Tivdak, is an antibody-drug conjugate used to treat cervical cancer. It is a combination of tisotumab, a monoclonal antibody against tissue factor, and monomethyl auristatin E (MMAE), a potent inhibitor of cell division. It is administered by infusion into a vein.
|
| Classification | Antibody |
| Drug class | synthetic analogs of the dolastatin series; monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1418731-10-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297841 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB16732 |
| UNII ID | T41737F88A (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 552 documents
View more details
Safety
Black-box Warning
Black-box warning for: Tivdak
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
701 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use